{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015205","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.868851+00:00","generated_at":"2026-06-16T00:50:18.340980+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ardelyx Q1 IBSRELA sales $11.4M, net loss $26.8M; XPHOZAH NDA resubmitted","bullets":["IBSRELA net product sales $11.4M in Q1 2023, up from $0.5M in Q1 2022.","Net loss $26.8M ($0.13/share) vs $28.1M ($0.21/share) in prior-year period.","Cash and investments $130.4M as of March 31, 2023; raised $51.9M from ATM offering.","XPHOZAH NDA resubmitted to FDA on April 17, 2023 for phosphate control in CKD patients on dialysis.","Licensed TGR5 agonist portfolio to METiS Therapeutics for $750K upfront + up to $243M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015205","json":"https://secwatch.observer/filing/0001628280-23-015205.json","markdown":"https://secwatch.observer/filing/0001628280-23-015205.md","text":"https://secwatch.observer/filing/0001628280-23-015205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/0001628280-23-015205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/ardx-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:50:18.340980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b2aeba959c737824096e2fd27e3b35e804eccd3","claim":"ARDELYX, INC. reported the quarter ended March 31, 2023 results: revenue $11.4 million, net income $26.8 million, EPS $(0.13) per share.","evidence_excerpt":"EX-99.1 (EX-99.1) --- Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/0001628280-23-015205-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$11.4 million"},{"label":"Net income","value":"$26.8 million"},{"label":"EPS","value":"$(0.13) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}